Harris & Harris Group Notes Metabolon's Collaboration With GSK

Harris & Harris Group Notes Metabolon's Collaboration With GSK

NEW YORK, May 13, 2014 (GLOBE NEWSWIRE) -- Harris & Harris Group, Inc.
(Nasdaq:TINY), an investor in transformative companies enabled by disruptive
science, notes the announcement by portfolio company, Metabolon, Inc., that it
has entered into a collaboration agreement with GlaxoSmithKline ("GSK") to
provide metabolomic profiling services and to collaborate on other research
projects leveraging Metabolon's DiscoveryHD4™ platform.

The collaboration will give GSK access to Metabolon's bioinformatics tools
along with the company's proprietary disease ontologies, as well as
visualization tools that will integrate metabolomics data with existing
genomics and proteomics data.

Metabolon has completed thousands of metabolomics studies across numerous
therapeutic areas and has developed expertise in metabolic pathways and
targets that are involved in the onset of disease and its progression.
Metabolon's press release may be viewed at
http://www.metabolon.com/news/PressReleases.aspx.

Detailed information about Harris & Harris Group and its holdings can be found
on its website at www.HHVC.com, on Facebook at www.facebook.com/harrisharrisvc
and by following us on Twitter @harrisandharrisgroup.

This press release may contain statements of a forward-looking nature relating
to future events. These forward-looking statements are subject to the inherent
uncertainties in predicting future results and conditions. These statements
reflect the Company's current beliefs, and a number of important factors could
cause actual results to differ materially from those expressed in this press
release. Please see the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2013, as well as subsequent filings, filed with the
Securities and Exchange Commission for a more detailed discussion of the risks
and uncertainties associated with the Company's business, including, but not
limited to, the risks and uncertainties associated with venture capital
investing and other significant factors that could affect the Company's actual
results. Except as otherwise required by Federal securities laws, the Company
undertakes no obligation to update or revise these forward-looking statements
to reflect new events or uncertainties. The references to the websites
www.HHVC.com and www.Facebook.com have been provided as a convenience, and the
information contained on such websites is not incorporated by reference into
this press release. Harris & Harris Group is not responsible for the contents
of third party websites.

CONTACT: DOUGLAS W. JAMISON
         TEL. NO. (212) 582-0900
 
Press spacebar to pause and continue. Press esc to stop.